1. Home
  2. DAVA vs KRRO Comparison

DAVA vs KRRO Comparison

Compare DAVA & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Endava plc (each representing one)

DAVA

Endava plc (each representing one)

HOLD

Current Price

$3.06

Market Cap

159.1M

Sector

Technology

ML Signal

HOLD

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

N/A

Current Price

$12.24

Market Cap

187.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DAVA
KRRO
Founded
2000
2014
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
159.1M
187.9M
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
DAVA
KRRO
Price
$3.06
$12.24
Analyst Decision
Buy
Buy
Analyst Count
9
12
Target Price
$13.50
$34.80
AVG Volume (30 Days)
167.7K
71.4K
Earning Date
05-19-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.07
N/A
P/E Ratio
$20.02
N/A
Revenue Growth
N/A
181.46
52 Week Low
$2.55
$5.20
52 Week High
$10.20
$55.89

Technical Indicators

Market Signals
Indicator
DAVA
KRRO
Relative Strength Index (RSI) 52.06 37.94
Support Level $2.64 $9.76
Resistance Level $3.22 $14.42
Average True Range (ATR) 0.14 0.77
MACD -0.01 -0.21
Stochastic Oscillator 42.05 6.93

Price Performance

Historical Comparison
DAVA
KRRO

About DAVA Endava plc (each representing one)

Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: